The next thing in prognostic molecular markers: MicroRNA signatures of cancer

Gut

Volumn 59, Issue 6, 2010, Pages 706-708

  Grady, William M ^a,b   Tewari, Muneesh ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; MESSENGER RNA; MICRORNA; MOLECULAR MARKER; NUCLEOTIDE; RNA;

CANCER CLASSIFICATION; CLINICAL FEATURE; COLON CARCINOMA; DNA SEQUENCE; DNA STRUCTURE; GENE CONTROL; GENE EXPRESSION; GENE MUTATION; GENE TARGETING; GENETIC CODE; HETEROZYGOSITY LOSS; HUMAN; INTRADUCTAL CARCINOMA; NOTE; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; RNA BINDING; RNA INTERFERENCE; TUMOR SUPPRESSOR GENE;

HUMANS; MICRORNAS; NEOPLASMS; PROGNOSIS; RNA, NEOPLASM; TUMOR MARKERS, BIOLOGICAL;

EID: 77953700486     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2009.200022     Document Type: Note

References (34)

1. Li X, Ying Z, Yaf Z, et al. Survival prediction of gastric cancer by a seven microRNA signature. Gut 2010;59:579-85.
2. Garzon R, Calin GA, Croce CM. MicroRNAs in cancer. Annu Rev Med 2009;60:167-79.
3. Bhatti I, Lee A, Lund J, et al. Small RNA: a large contributor to carcinogenesis? J Gastrointest Surg 2009;13:1379-88.
4. Slaby O, Svoboda M, Michalek J, et al. MicroRNAs in colorectal cancer: translation of molecular biology into clinical application. Mol Cancer 2009;8:102.
5. Iorio MV, Croce CM. MicroRNAs in cancer: small molecules with a huge impact. J Clin Oncol 2009;27:5848-56.
6. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281-97.
7. Carleton M, Cleary MA, Linsley PS. MicroRNAs and cell cycle regulation. Cell Cycle 2007;6:2127-32.
8. Lau NC, Lim LP, Weinstein EG, et al. An abundant class of tiny RNAs with probable regulatory roles in Caenorhabditis elegans. Science 2001;294:858-62.
9. Poy MN, Eliasson L, Krutzfeldt J, et al. A pancreatic islet-specific microRNA regulates insulin secretion. Nature 2004;432:226-30.
10. Jin P, Zarnescu DC, Ceman S, et al. Biochemical and genetic interaction between the fragile X mental retardation protein and the microRNA pathway. Nat Neurosci 2004;7:113-17.
11. Bullrich F, Fujii H, Calin G, et al. Characterization of the 13q14 tumor suppressor locus in CLL: identification of ALT1, an alternative splice variant of the LEU2 gene. Cancer Res 2001;61:6640-8.
12. Cummins JM, He Y, Leary RJ, et al. The colorectal microRNAome. Proc Natl Acad Sci U S A 2006;103:3687-92.
13. Schetter AJ, Leung SY, Sohn JJ, et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 2008;299:425-36.
14. Volinia S, Calin GA, Liu CG, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 2006;103:2257-61.
15. Lanza G, Ferracin M, Gafa R, et al. mRNA/microRNA gene expression profile in microsatellite unstable colorectal cancer. Mol Cancer 2007;6:54.
16. Gaur A, Jewell DA, Liang Y, et al. Characterization of microRNA expression levels and their biological correlates in human cancer cell lines. Cancer Res 2007;67:2456-68.
17. Sayed D, Rane S, Lypowy J, et al. MicroRNA-21 targets Sprouty2 and promotes cellular outgrowths. Mol Biol Cell 2008;19:3272-82.
18. Visone R, Petrocca F, Croce CM. Micro-RNAs in gastrointestinal and liver disease. Gastroenterology 2008;135:1866-9.
19. Ji Q, Hao X, Meng Y, et al. Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres. BMC Cancer 2008;8:266.
20. Xiao B, Guo J, Miao Y, et al. Detection of miR-106a in gastric carcinoma and its clinical significance. Clin Chim Acta 2009;400:97-102.
21. Katada T, Ishiguro H, Kuwabara Y, et al. microRNA expression profile in undifferentiated gastric cancer. Int J Oncol 2009;34:537-42.
22. Luo H, Zhang H, Zhang Z, et al. Down-regulated miR-9 and miR-433 in human gastric carcinoma. J Exp Clin Cancer Res 2009;28:82.
23. Guo J, Miao Y, Xiao B, et al. Differential expression of microRNA species in human gastric cancer versus non-tumorous tissues. J Gastroenterol Hepatol 2009;24:652-7.
24. Motoori M, Takemasa I, Yano M, et al. Prediction of recurrence in advanced gastric cancer patients after curative resection by gene expression profiling. Int J Cancer 2005;114:963-8.
25. Fareed KR, Kaye P, Soomro IN, et al. Biomarkers of response to therapy in oesophago-gastric cancer. Gut 2009;58:127-43.
26. Chen CN, Lin JJ, Chen JJ, et al. Gene expression profile predicts patient survival of gastric cancer after surgical resection. J Clin Oncol 2005;23:7286-95.
27. Yamada Y, Arao T, Gotoda T, et al. Identification of prognostic biomarkers in gastric cancer using endoscopic biopsy samples. Cancer Sci 2008;99:2193-9.
28. Shibata A, Parsonnet J, Longacre TA, et al. CagA status of Helicobacter pylori infection and p53 gene mutations in gastric adenocarcinoma. Carcinogenesis 2002;23:419-24. (Pubitemid 34257621)
29. Okusa Y, Ichikura T, Mochizuki H. Prognostic impact of stromal cell-derived urokinase-type plasminogen activator in gastric carcinoma. Cancer 1999;85:1033-8.
30. Linder N, Haglund C, Lundin M, et al. Decreased xanthine oxidoreductase is a predictor of poor prognosis in early-stage gastric cancer. J Clin Pathol 2006;59:965-71.
31. Resnick MB, Gavilanez M, Newton E, et al. Claudin expression in gastric adenocarcinomas: a tissue microarray study with prognostic correlation. Hum Pathol 2005;36:886-92.
32. Kido S, Kitadai Y, Hattori N, et al. Interleukin 8 and vascular endothelial growth factor - prognostic factors in human gastric carcinomas? Eur J Cancer 2001;37:1482-7.
33. Xiangming C, Hokita S, Natsugoe S, et al. p21 Expression is a prognostic factor in patients with p53-negative gastric cancer. Cancer Lett 2000;148:181-8.
34. Locker GY, Hamilton S, Harris J, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006;24:5313-27.